0001104659-23-021008.txt : 20230214 0001104659-23-021008.hdr.sgml : 20230214 20230214102618 ACCESSION NUMBER: 0001104659-23-021008 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230214 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230214 DATE AS OF CHANGE: 20230214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BICYCLE THERAPEUTICS plc CENTRAL INDEX KEY: 0001761612 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38916 FILM NUMBER: 23624072 BUSINESS ADDRESS: STREET 1: BLOCKS A & B, PORTWAY BUILDING STREET 2: GRANTA PARK, GREAT ABINGTON CITY: CAMBRIDGE STATE: X0 ZIP: CB21 6GS BUSINESS PHONE: 011441223261503 MAIL ADDRESS: STREET 1: BLOCKS A & B, PORTWAY BUILDING STREET 2: GRANTA PARK, GREAT ABINGTON CITY: CAMBRIDGE STATE: X0 ZIP: CB21 6GS FORMER COMPANY: FORMER CONFORMED NAME: BICYCLE THERAPEUTICS Ltd DATE OF NAME CHANGE: 20181212 8-K 1 tm236546d1_8k.htm FORM 8-K
0001761612 false 00-0000000 true 0001761612 2023-02-14 2023-02-14 0001761612 us-gaap:CommonStockMember 2023-02-14 2023-02-14 0001761612 bcyc:AmericanDepositarySharesMember 2023-02-14 2023-02-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

February 14, 2023

Date of Report (Date of earliest event reported)

 

Bicycle Therapeutics plc

(Exact name of registrant as specified in its charter)

 

England and Wales   001-38916   Not applicable

(State or other jurisdiction
of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

Blocks A & B, Portway Building,
Granta Park Great Abington, Cambridge
United Kingdom

CB21 6GS
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: +44 1223 261503

  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Ordinary shares, nominal value £0.01 per share n/a The Nasdaq Stock Market LLC*
American Depositary Shares, each representing one ordinary share, nominal value £0.01 per share BCYC The Nasdaq Stock Market LLC

 

* Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). 

 

Emerging growth company    ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 8.01Other Events

 

On February 14, 2023, Bicycle Therapeutics plc (the “Company”) issued a press release announcing the monotherapy Phase I dose escalation results of the ongoing Phase I/II trial of BT8009 in patients with solid tumors expressing Nectin-4. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 8.01 by reference.

 

The Company also posted an updated corporate presentation on its website, which can be accessed by visiting the “Presentation + Events” section at investors.bicycletherapeutics.com.

 

The information furnished under this Item 8.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filing.

 

Item 9.01Financial Statements and Exhibits

 

(d)       Exhibits

 

Exhibit No.   Description
99.1   Press Release dated February 14, 2023
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)  

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: February 14, 2023 Bicycle therapeutics plc
   
  By: /s/ Lee Kalowski
  Name: Lee Kalowski
  Title: Chief Financial Officer

 

 

 EX-99.1 2 tm236546d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

Bicycle Therapeutics Announces Phase I Dose Escalation Results from Ongoing Phase I/II Study of BT8009

 

50% overall response rate (ORR) and 75% clinical benefit rate, including one complete response in urothelial cancer at the 5 mg/m2 dose on an intent-to-treat (ITT) basis

 

As of January 2023, median duration of response (mDOR) is estimated to be approximately 14 months among urothelial cancer patients in the 5 mg/m2 cohort

 

Confirmed RECIST responses in non-small cell lung cancer (NSCLC) and breast cancer patients

 

Conference call scheduled for 8:00 a.m. ET

 

CAMBRIDGE, England, & BOSTON, February 14, 2023 – Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced monotherapy Phase I dose escalation results of the ongoing Phase I/II trial of BT8009, a novel BTC™ targeting Nectin-4. The results will be presented at the 2023 American Society for Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium on Friday, February 17, 2023 in San Francisco, California. Today at 8:00 a.m. ET, the Company will host a conference call with BT8009 investigator Dr. Capucine Baldini and Dr. Daniel Petrylak to discuss the data being presented.

 

“We are encouraged by the Phase I dose escalation results as they continue to demonstrate the potential for BT8009 to be best-in-class for the treatment of urothelial cancer based on the observed anti-tumor activity and tolerability profile as well as the potential to treat other tumor types with significant unmet need,” said Kevin Lee, Ph.D., Chief Executive Officer. “Previously, we had reported a confirmed partial response in a non-small cell lung cancer patient and today we are pleased to announce a confirmed partial response in a breast cancer patient. Both of these patients are Nectin-4 positive. We are continuing to move forward with the dose expansion and Phase II portion of the clinical trial and look forward to providing an update by the end of 2023.”

 

“These data reaffirm the possibility for BT8009 to become a significant new treatment option for patients,” said Capucine Baldini, M.D., Medical Oncologist, Gustave Roussy. “The anti-tumor activity observed to date in heavily pre-treated urothelial, lung and breast cancer patients shows that BT8009’s Nectin-4-targeting properties make it a potentially differentiated treatment option compared to other available treatments.”

 

“BT009 has the potential to become an important player in the treatment landscape for urothelial cancer and other solid tumors,” said Daniel Petrylak, M.D., Professor of Medicine and Urology, Yale University. “Clinicians need differentiated treatments for patients that can offer lower rates of rash and neuropathy thus leading to longer durations of treatment.  Given the preliminary tolerability and response pattern with BT8009 in this Phase I dose escalation, it justifies exploring BT8009 both as a monotherapy and in combination in the ongoing expansion cohorts.”

 

 

 

 

BT8009, a BTC targeting Nectin-4, has demonstrated anti-tumor activity in heavily pre-treated urothelial, lung and breast cancer patients with signs of differentiation compared to antibody-based approaches. Bicycle established two recommended Phase II doses (RP2Ds) at 5 mg/m2 weekly and 7.5 mg/m2 2 weeks on, 1-week off (over a 21-day cycle). The company is currently focusing its efforts on the 5 mg/m2 weekly dose and enrollment in the expansion cohorts remains ongoing.

 

·Preliminary signs of anti-tumor activity observed. As of the September 20, 2022 data cut off, 49 patients were dosed in the Phase I escalation portion of the ongoing Phase I/II trial with a median of three prior lines of therapy.

 

oA total of 24 urothelial cancer patients were dosed. Of these, eight patients were dosed at the RP2D of 5 mg/m2 weekly.

 

§Among these eight patients, one patient had a complete response (13%), and three patients had a partial response (38%) under the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, resulting in an ITT ORR of 50%. Two additional patients had stable disease for over 16 weeks, resulting in a clinical benefit rate (CBR) of 75%. The remaining two patients in the cohort consisted of one stable disease and one non-evaluable patient.

 

§Of the eight urothelial patients dosed at 5 mg/m2 weekly, seven were response evaluable. Amongst these seven patients, all (100%) were observed to have at least some degree of tumor shrinkage, including the four with a RECIST version 1.1 response (57% ORR on a response-evaluable basis).

 

§As of January 2023, mDOR is estimated to be approximately 14 months. Two out of four responders in this cohort remain on therapy with ongoing responses.

 

oResponse rates in urothelial patients in the 7.5 mg/m2 2 weeks on, 1-week off (over a 21-day cycle) and 10 mg/m2 every other week cohort were consistent with that of the 5 mg/m2 weekly cohort on an ITT basis. One of two patients in the 7.5 mg/m2 2 weeks on, 1-week off (over a 21-day cycle) cohort had a partial response and two of four patients in the 10 mg/m2 every other week cohort had a partial response, for an ORR of 50% in each of these cohorts. Both of these cohorts deliver the same amount of MMAE payload as the 5 mg/m2 weekly dose over a six-week period.

 

oConfirmed RECIST response in an NSCLC patient. A confirmed partial response was observed in a 76-year-old patient with Nectin-4 positive metastatic adenocarcinoma. The patient entered the 7.5 mg/m2 2 weeks on, 1-week off (over a 21-day cycle) cohort after four prior lines of therapy, including a checkpoint inhibitor. As of the September 20, 2022 data cutoff, the patient remains on therapy with an ongoing response.

 

oConfirmed RECIST response in a breast cancer patient. A confirmed partial response was observed in a 79-year-old patient with Nectin-4 positive metastatic adenocarcinoma. The patient entered the 10 mg/m2 every other week cohort after one prior line of therapy. As of December 2022, the patient remains on therapy with an ongoing response.

 

 

 

 

·BT8009 was well tolerated across all 49 patients in the study, with a low incidence of adverse events common to antibody-based approaches. The most common treatment-related adverse events across the study were gastroenterologically related and fatigue. Across all patients at all doses, there was a low incidence of skin rash of any form, eye disorders, neuropathy of any form and no cases of pneumonitis in any patient at any dose. The most common Grade 3 or higher treatment-related adverse event was neutropenia: seven cases or 14%; four of these were at doses above the RP2Ds. There were three subjects with serious adverse events (SAEs) at or above Grade 3 that were drug related (6%). Of these, none was in the 5 mg/m2 cohort. Median percentage relative dose intensity was 99%, reflecting a low level of dose modifications especially for a Phase I dose escalation trial in a heavily pre-treated population.

 

·BT8009 well tolerated at or below the two RP2Ds. At or below the RP2Ds of 5 mg/m2 weekly and 7.5 mg/m2 2 weeks on, 1-week off (over a 21-day cycle), treatment-related dose modifications were rare. There were no treatment-related discontinuations. The incidence of Grade 3 or higher related adverse events at or below the two RP2Ds was low. At the 5 mg/m2 weekly dose, there were no cases of Grade 3 or higher skin rash, eye disorders, neuropathy or pneumonitis.

 

Bicycle advancing BT8009 in ongoing expansion cohorts. In November 2022, Bicycle announced the dosing of the first patient in the part B dose expansion portion of the Phase I/II trial. Up to 66 patients will be enrolled in the initial monotherapy expansion cohorts, with the ability to further expand enrollment based on results from these cohorts. These monotherapy cohorts include urothelial cancer patients who are enfortumab vedotin (EV) naïve and those who are EV exposed, as well as cohorts in ovarian, triple negative breast and non-small cell lung cancers. A Phase II trial of BT8009 in combination with pembrolizumab remains on track to commence this year.

 

Poster Presentation Details

 

Title: BT8009-100: A Phase I/II Study of a Novel Bicyclic Peptide and MMAE Conjugate BT8009 in Patients with Advanced Malignancies Associated with Nectin-4 Expression, Including Urothelial Cancer

Abstract #: 498
Presenter: Capucine Baldini, M.D., on behalf of the BT8009-100 investigators
Session Title: Poster Session B: Prostate Cancer and Urothelial Carcinoma
Date/Time: Friday, February 17, 3:30 p.m. to 5:00 p.m.; 8:15 p.m. to 9:15 p.m. ET

 

Conference Call Details

 

Bicycle Therapeutics will host a conference call and webcast today, February 14, 2023 at 8:00 a.m. ET to review the data being presented. To access the call, please dial (866) 652-5200 (domestic) or (412) 317-6060 (international) and provide the Conference ID 10174689. A live webcast of the presentation will be available on the Investors & Media section of the Bicycle website, bicycletherapeutics.com.

 

About Bicycle Therapeutics

 

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC™) targeting EphA2; BT8009, a second-generation BTC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a Bicycle TICA™ targeting Nectin-4 and agonizing CD137, in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, MA. For more information, visit bicycletherapeutics.com.

 

 

 

 

Forward-Looking Statements

 

This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the potential of BT8009 to target and kill cancer tumor cells; the initiation, progress, and timing of clinical trials of BT8009 and pursuit of additional indications for and further clinical development of this product candidate. Bicycle may not actually achieve the intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: whether the outcomes of preclinical studies will be predictive of clinical trial results; the risk that trials and studies may be delayed and may not have satisfactory outcomes; and other important factors, any of which could cause Bicycle’s actual results to differ from those contained in the forward-looking statements, are described in greater detail in the section entitled “Risk Factors” in Bicycle’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 3, 2022, as well as in other filings Bicycle may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Bicycle expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

 

Investors:
David Borah, CFA
SVP, Capital Markets & Corporate Communications

david.borah@bicycletx.com

617-203-8300

 

Media:
Argot Partners
Sarah Sutton

bicycle@argotpartners.com

212-600-1902

 

 

 

 EX-101.SCH 3 bcyc-20230214.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 bcyc-20230214_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 bcyc-20230214_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] Common Stock [Member] American Depositary Shares [Member] Statement [Table] Document Information [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] American Depositary Shares EX-101.PRE 6 bcyc-20230214_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 tm236546d1_ex99-1img001.jpg GRAPHIC begin 644 tm236546d1_ex99-1img001.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover
Feb. 14, 2023
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 14, 2023
Entity File Number 001-38916
Entity Registrant Name Bicycle Therapeutics plc
Entity Central Index Key 0001761612
Entity Tax Identification Number 00-0000000
Entity Incorporation, State or Country Code X0
Entity Address, Address Line One Blocks A & B, Portway Building
Entity Address, Address Line Two Granta Park Great Abington
Entity Address, City or Town Cambridge
Entity Address, Country GB
Entity Address, Postal Zip Code CB21 6GS
City Area Code +44
Local Phone Number 1223 261503
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock [Member]  
Document Information [Line Items]  
Title of 12(b) Security Ordinary shares, nominal value £0.01 per share
No Trading Symbol Flag true
Security Exchange Name NASDAQ
American Depositary Shares [Member]  
Document Information [Line Items]  
Title of 12(b) Security American Depositary Shares, each representing one ordinary share, nominal value £0.01 per share
Trading Symbol BCYC
Security Exchange Name NASDAQ
XML 9 tm236546d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001761612 2023-02-14 2023-02-14 0001761612 us-gaap:CommonStockMember 2023-02-14 2023-02-14 0001761612 bcyc:AmericanDepositarySharesMember 2023-02-14 2023-02-14 iso4217:USD shares iso4217:USD shares 0001761612 false 00-0000000 true 8-K 2023-02-14 Bicycle Therapeutics plc X0 001-38916 Blocks A & B, Portway Building Granta Park Great Abington Cambridge GB CB21 6GS +44 1223 261503 false false false false Ordinary shares, nominal value £0.01 per share NASDAQ American Depositary Shares, each representing one ordinary share, nominal value £0.01 per share BCYC NASDAQ false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 3 24 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://bicycletherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm236546d1_8k.htm bcyc-20230214.xsd bcyc-20230214_def.xml bcyc-20230214_lab.xml bcyc-20230214_pre.xml tm236546d1_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm236546d1_8k.htm": { "axisCustom": 0, "axisStandard": 1, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021q4": 26 }, "contextCount": 3, "dts": { "definitionLink": { "local": [ "bcyc-20230214_def.xml" ] }, "inline": { "local": [ "tm236546d1_8k.htm" ] }, "labelLink": { "local": [ "bcyc-20230214_lab.xml" ] }, "presentationLink": { "local": [ "bcyc-20230214_pre.xml" ] }, "schema": { "local": [ "bcyc-20230214.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 65, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 1, "memberStandard": 1, "nsprefix": "bcyc", "nsuri": "http://bicycletherapeutics.com/20230214", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm236546d1_8k.htm", "contextRef": "From2023-02-14to2023-02-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://bicycletherapeutics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm236546d1_8k.htm", "contextRef": "From2023-02-14to2023-02-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "bcyc_AmericanDepositarySharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "American Depositary Shares", "label": "American Depositary Shares [Member]" } } }, "localname": "AmericanDepositarySharesMember", "nsuri": "http://bicycletherapeutics.com/20230214", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001104659-23-021008-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-021008-xbrl.zip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end